Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neuroblastoma 7Lymphoma, B-Cell 5Lymphoma 5Rhabdoid Tumor 3Neoplasms 3Medulloblastoma 3Leukemia, Myeloid, Acute 3Leukemia 3Sarcoma, Ewing 2Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pinealoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Germ Cell and Embryonal 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Ganglioneuroblastoma 2Ependymoma 2Enteropathy-Associated T-Cell Lymphoma 2Brain Neoplasms 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1

Interventions

Cyclophosphamide 13Prednisone 10N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Doxorubicin 9Vincristine 8Azacitidine 6romidepsin 5Gemcitabine 5Brentuximab Vedotin 5fludarabine 4Etoposide 4Dexamethasone 4pembrolizumab 3belinostat 3Lenalidomide 3Biopsy 310-propargyl-10-deazaaminopterin 3tazemetostat 2ruxolitinib 2ixazomib 2duvelisib 2Nivolumab 2Bendamustine Hydrochloride 2venetoclax 1tislelizumab 1thymoglobulin 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × etoposide phosphate × 1 year × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡